Artikel ; Online: Nonclinical Investigation of Cytokine Mitigation Strategies for T-cell-Engaging Bispecifics in the Cynomolgus Macaque.
Journal of immunotherapy (Hagerstown, Md. : 1997)
2024 Band 47, Heft 5, Seite(n) 160–171
Abstract: Summary: T-cell-directed cancer therapies such as T-cell-engaging bispecifics (TCBs) are commonly associated with cytokine release syndrome and associated clinical signs that can limit their tolerability and therapeutic benefit. Strategies for reducing ... ...
Abstract | Summary: T-cell-directed cancer therapies such as T-cell-engaging bispecifics (TCBs) are commonly associated with cytokine release syndrome and associated clinical signs that can limit their tolerability and therapeutic benefit. Strategies for reducing cytokine release are therefore needed. Here, we report on studies performed in cynomolgus monkeys to test different approaches for mitigating cytokine release with TCBs. A "priming dose" as well as subcutaneous dosing reduced cytokine release compared with intravenous dosing but did not affect the intended T-cell response to the bispecific. As another strategy, cytokines or cytokine responses were blocked with an anti-IL-6 antibody, dexamethasone, or a JAK1/TYK2-selective inhibitor, and the effects on toxicity as well as T-cell responses to a TCB were evaluated. The JAK1/TYK2 inhibitor and dexamethasone prevented CRS-associated clinical signs on the day of TCB administration, but the anti-IL-6 had little effect. All interventions allowed for functional T-cell responses and expected damage to target-bearing tissues, but the JAK1/TYK2 inhibitor prevented the upregulation of activation markers on T cells, suggesting the potential for suppression of T-cell responses. Our results suggest that short-term prophylactic dexamethasone treatment may be an effective option for blocking cytokine responses without affecting desired T-cell responses to TCBs. |
---|---|
Mesh-Begriff(e) | Animals ; Macaca fascicularis ; Antibodies, Bispecific/pharmacology ; T-Lymphocytes/immunology ; T-Lymphocytes/drug effects ; T-Lymphocytes/metabolism ; Cytokines/metabolism ; Dexamethasone/pharmacology ; Humans ; Cytokine Release Syndrome/drug therapy ; Cytokine Release Syndrome/etiology ; Interleukin-6/metabolism ; Lymphocyte Activation/drug effects ; Lymphocyte Activation/immunology ; Neoplasms/immunology ; Neoplasms/drug therapy |
Chemische Substanzen | Antibodies, Bispecific ; Cytokines ; Dexamethasone (7S5I7G3JQL) ; Interleukin-6 |
Sprache | Englisch |
Erscheinungsdatum | 2024-04-02 |
Erscheinungsland | United States |
Dokumenttyp | Journal Article ; Research Support, Non-U.S. Gov't |
ZDB-ID | 1064067-8 |
ISSN | 1537-4513 ; 1053-8550 ; 1524-9557 |
ISSN (online) | 1537-4513 |
ISSN | 1053-8550 ; 1524-9557 |
DOI | 10.1097/CJI.0000000000000512 |
Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Zusatzmaterialien
Kategorien
Verfügbar in ZB MED Köln/Königswinter
Zs.A 1778: Hefte anzeigen | Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.